背景與目的：肝細胞癌(hepatocellular carcinoma, HCC)為一種受到許多環境與遺傳因子影響之複雜性疾病。過去已有許多的loss-of-heterozygosity的研究指出在4q染色體上存在與HBV相關之HCC抑癌基因。本研究室先前的連鎖分析已在4q25位置發現初步顯著連鎖訊息。
材料與方法：我們以連鎖高峰為中心橫跨10 cM區域進行相關性研究，選擇14個單核苷多型性(single nucleotide polymorphism, SNPs)標記，分別對989名HBsAg陽性男性病例及956名HBsAg陽性之男性對照個案進行分析。
結果：以發病年齡進行分層分析，我們發現在發病年齡介於41~50歲之早發型的HCC中，SNP2在發病年齡介於41~50歲中，即使在校正多重檢定後仍具有顯著意義(P =.0003)。以相鄰標記進行半套體分析中，發現SNP1-SNP2在發病年齡介於41~50歲 (P value=.0006)及SNP8-SNP9在發病年齡>60歲 (P value=.0009)之半套体經過校正多重檢定後仍具有顯著意義。
結論：本研究發現SNP1-SNP2及SNP9-SNP9半套體和HCC顯著相關，但由於本研究的基因標記之分佈密度不夠密集，且涵蓋的區域不夠廣闊，未來有必要選取分佈更密且涵蓋更廣的SNP標記進行分析。

Background and Aim: Hepatocellular carcinoma (HCC) is a complex disease involving both environmental and genetic factors. Several loss-of-heterozygosity studies have suggested the existence of a tumor suppressor gene for HBV-related HCC on chromosome 4q. Our previous linkage study in HCC multiplex families has found a significant linkage signal on 4q25. The aim of this present study was to finely map the presumed HCC-susceptibility locus on 4q by using a large-scale case-control study.
Materials and Method: A total of 989 male HBsAg-positive HCC cases and 956 age-sex matched HBsAg-positive controls were included. We analyzed 14 single nucleotide polymorphisms (SNPs) distributed throughout the 2-HLOD-drop internal (~10 cM) around the linkage peak identified by our previous study.
Result: overall, none of the 14 SNPs were associated with HCC. However, SNP2 was significantly associated with early-onset HCC diagnosed between 41-50 years of age (P=.0003) this association remained statistically significant even after adjusting multiple comparisons by use of calculating false discovery rate. Haplotype analysis revealed that haplotype SNP1-SNP2 was associated with HCC diagnosed between 41-50 years of age (P=.0006), and SNP8-SNP9 was associated with HCC diagnosed at age >60 (P=0.0009).
Conclusions: We found haplotypes SNP1-SNP2 and SNP8-SNP9 were significantly associated with HCC. Further association study with a higher density of markers, which focused on a broader chromosomal region, is warranted.

前言 1
材料與方法 3
研究個案 3
問卷資料 4
實驗分析 4
分析方法 5
結果 6
環境因子在不同發病年齡知病例的分佈 6
單一基因標記分佈 6
連鎖不平衡分析 7
半套體分析 7
討論 8
參考文獻 11
表ㄧ 不同發病年齡之病例組環境因子分佈 21
表二 病例與對照組單一標記之基因頻率分佈 22
表三 不同發病年齡之半套體分析 23
圖一 24
圖二 25
圖三 26
附錄 27

1.Muir CS, Nectoux J. International patterns of cancer. In: Schottenfeld D, Fraumenj JF Jr, editor. Cancer epidemiology and prevention . 2nd ed. New York : Oxford University Press; 1996;141-67.
2.Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer. 1993;54:594-606.
3.Chen CJ, Chen DS. Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. Hepatology.2003;36:1046-9.
4.Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, Chen PJ, Hsiao TJ, Lee PH, Chen CJ. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst.2000;92:1159-64.
5.Yu MW, Chang HC, Chen PJ, Liu CJ, Liaw YF, Lin SM, Lee SD, Lin SC, Lin CL, Chen CJ. Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. Int J Epidemiol. 2002;31:1008-15.
6.Gao Y, Jiang Q, Zhou X, Ding B, Wang R, Zhao G, Chen Y. HBV infection and familial aggregation of liver cancer: an analysis of case-control family study. Cancer Causes Control.2004;15:845-50.
7.Shen FM, Lee MK, Gong HM, Cai XQ, King MC. Complex segregation analysis of primary hepatocellular carcinoma in Chinese families: interaction of inherited susceptibility and hepatitis B viral infection. Am J Hum Genet.1991;49:88-93.
8.Cai RL, Meng W, Lu HY, Lin WY, Jiang F, Shen FM. Segregation analysis of hepatocellular carcinoma in a moderately high-incidence area of East China. World J Gastroenterol.2003;9:2428-32.
9.Yang P, Buetow KH, Lustbader ED, Lanier AP, McMahon BJ, Alberts S, McGlynn KA. Evidence for a major locus modifying risk for primary hepatocellular carcinoma. Am J Hum Genet.1990;47(supp):A25.
10.Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa.Nature.1991;350:429-31.
11.Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature.1991;350:427-8.
12.Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res.1992;52:6358-64.
13.Buetow KH, Sheffield VC, Zhu M, Zhou T, Shen FM, Hino O, Smith M, McMahon BJ, Lanier AP, London WT, et al. Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc Natl Acad Sci U S A.1992;89:9622-6.
14.Hayashi H, Sugio K, Matsumata T, Adachi E, Takenaka K, Sugimachi K. The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan. Hepatology.1995;22:1702-7.
15.Mise K, Tashiro S, Yogita S, Wada D, Harada M, Fukuda Y, Miyake H, Isikawa M, Izumi K, Sano N. Assessment of the biological malignancy of hepatocellular carcinoma: relationship to clinicopathological factors and prognosis. Clin Cancer Res.1998;4:1475-82.
16.Honda K, Sbisa E, Tullo A, Papeo PA, Saccone C, Poole S, Pignatelli M, Mitry RR, Ding S, Isla A, Davies A, Habib NA. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br J Cancer.1998;77:776-82.
17.Sugo H, Takamori S, Kojima K, Beppu T, Futagawa S. The significance of p53 mutations as an indicator of the biological behavior of recurrent hepatocellular carcinomas. Surg Today.1999;29:849-55.
18.Miyoshi Y, Iwao K, Nagasawa Y, Aihara T, Sasaki Y, Imaoka S, Murata M, Shimano T, Nakamura Y. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res. 1998;58:2524-7.
19.de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A, Perret C. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A.1998;95:8847-51.
20.Legoix P, Bluteau O, Bayer J, Perret C, Balabaud C, Belghiti J, Franco D, Thomas G, Laurent-Puig P, Zucman-Rossi J. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene.1999;18:4044-6.
21.Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, Sasaki Y, Imaoka S, Murata M, Shimano T, Yamaoka Y, Nakamura Y. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet.2000;24:245-50.
22.Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI, Ross JA, Liu W. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene.2002;21:4863-71.
23.Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis.Am J Pathol.2000;157:763-70.
24.Neiswanger K, Kaplan B, Hill SY. Exclusion of linkage between alcoholism and the MNS blood group region on chromosome 4q in multiplex families. Am J Med Genet.1995;60:72-9.
25.Jornvall H, Nordling E, Persson B. Multiplicity of eukaryotic ADH and other MDR forms. Chem Biol Interact.2003;143-144:255-61.
26.Edman K, Maret W. Alcohol dehydrogenase genes: restriction fragment length polymorphisms for ADH4 (pi-ADH) and ADH5 (chi-ADH) and construction of haplotypes among different ADH classes. Hum Genet.1992;90:395-401.
27.Cotton RW, Goldman D. Review of the molecular biology of the human alcohol dehydrogenase genes and gene products. Adv Alcohol Subst Abuse. 1988;7:171-82.
28.Okabe H, Ikai I, Matsuo K, Satoh S, Momoi H, Kamikawa T, Katsura N, Nishitai R, Takeyama O, Fukumoto M, Yamaoka Y. Comprehensive allelotype study of hepatocellular carcinoma: potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors. Hepatology. 2000;31:1073-9.
29.Li SP, Wang HY, Li JQ, Zhang CQ, Feng QS, Huang P, Yu XJ, Huang LX, Liang QW, Zeng YX. Genome-wide analyses on loss of heterozygosity in hepatocellular carcinoma in Southern China. J Hepatol.2001;34:840-9.
30.Konishi M, Kikuchi-Yanoshita R, Tanaka K, Sato C, Tsuruta K, Maeda Y, Koike M, Tanaka S, Nakamura Y, Hattori N, et al. Genetic changes and histopathological grades in human hepatocellular carcinomas. Jpn J Cancer Res.1993;84:893-9.
31.Yumoto Y, Hanafusa T, Hada H, Morita T, Ooguchi S, Shinji N, Mitani T, Hamaya K, Koide N, Tsuji T. Loss of heterozygosity and analysis of mutation of p53 in hepatocellular carcinoma. J Gastroenterol Hepatol.1995;10:179-85.
32.Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, Thomas G, Bioulac-Sage P, Zucman-Rossi J. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology.2001;120:1763-73.
33.Piao Z, Park C, Park JH, Kim H. Deletion mapping of chromosome 4q in hepatocellular carcinoma. Int J Cancer.1998;79:356-60.
34.Yeh SH, Chen PJ, Lai MY, Chen DS. Allelic loss on chromosomes 4q and 16q in hepatocellular carcinoma: association with elevated alpha-fetoprotein production. Gastroenterology.1996;110:184-92.
35.Polascik TJ, Cairns P, Chang WY, Schoenberg MP, Sidransky D. Distinct regions of allelic loss on chromosome 4 in human primary bladder carcinoma. Cancer Res. 1995;55:5396-9.
36.Mitra AB, Murty VV, Li RG, Pratap M, Luthra UK, Chaganti RS. Allelotype analysis of cervical carcinoma. Cancer Res.1994;54:4481-7.
37.Pershouse MA, El-Naggar AK, Hurr K, Lin H, Yung WK, Steck PA. Deletion mapping of chromosome 4 in head and neck squamous cell carcinoma. Oncogene. 1997;14:369-73.
38.Lundorf MD, Buttenschon HN, Foldager L, Blackwood DH, Muir WJ, Murray V, Pelosi AJ, Kruse TA, Ewald H, Mors O. Mutational screening and association study of glutamate decarboxylase 1 as a candidate susceptibility gene for bipolar affective disorder and schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2004;135B:94-101.
39.Numakawa T, Yagasaki Y, Ishimoto T, Okada T, Suzuki T, Iwata N, Ozaki N, Taguchi T, Tatsumi M, Kamijima K, Straub RE, Weinberger DR, Kunugi H, Hashimoto R. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet.2004;13:2699-708.
40.Jiang Y, Wilk JB, Borecki I, Williamson S, DeStefano AL, Xu G, Liu J, Ellison RC, Province M, Myers RH. Common variants in the 5'' region of the leptin gene are associated with body mass index in men from the National Heart, Lung, and Blood Institute Family Heart Study. Am J Hum Genet.2004;75:220-30.
41. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, Manolescu A, Jonsdottir S, Jonsdottir T, Gudmundsdottir T, Bjarnadottir SM, Einarsson OB, Gudjonsdottir HM, Hawkins M, Gudmundsson G, Gudmundsdottir H, Andrason H, Gudmundsdottir AS, Sigurdardottir M, Chou TT, Nahmias J, Goss S, Sveinbjornsdottir S, Valdimarsson EM, Jakobsson F, Agnarsson U, Gudnason V, Thorgeirsson G, Fingerle J, Gurney M, Gudbjartsson D, Frigge ML, Kong A, Stefansson K, Gulcher JR. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet.2003;35:131-8.
42.Golden B, Levin L, Ban Y, Concepcion E, Greenberg DA, Tomer Y. Genetic analysis of families with autoimmune diabetes and thyroiditis: evidence for common and unique genes. J Clin Endocrinol Metab.2005; 10.1210/jc.2004-2236
43. Bergholdt R, Nerup J, Pociot F. Fine mapping of a region on chromosome 21q21.11-q22.3 showing linkage to type 1 diabetes. J Med Genet.2005 ;42:17-25.
44.Wang H, Chu W, Das SK, Zheng Z, Hasstedt SJ, Elbein SC. Molecular screening and association studies of retinoid-related orphan receptor gamma (RORC): a positional and functional candidate for type 2 diabetes. Mol Genet Metab.2003;79:176-82.
45.Silander K, Mohlke KL, Scott LJ, Peck EC, Hollstein P, Skol AD, Jackson AU, Deloukas P, Hunt S, Stavrides G, Chines PS, Erdos MR, Narisu N, Conneely KN, Li C, Fingerlin TE, Dhanjal SK, Valle TT, Bergman RN, Tuomilehto J, Watanabe RM, Boehnke M, Collins FS. Genetic variation near the hepatocyte nuclear factor-4 alpha gene predicts susceptibility to type 2 diabetes. Diabetes. 2004;53:1141-9.
46.Mansur AH, Bishop DT, Holgate ST, Markham AF, Morrison JF. Linkage/association study of a locus modulating total serum IgE on chromosome 14q13-24 in families with asthma. Thorax.2004;59:876-82.
47.Noguchi E, Yokouchi Y, Zhang J, Shibuya K, Shibuya A, Bannai M, Tokunaga K, Doi H, Tamari M, Shimizu M, Shirakawa T, Shibasaki M, Ichikawa K, Arinami T. Positional Identification of an Asthma Susceptibility Gene on Human Chromosome 5q33. Am J Respir Crit Care Med. 2005; 10.1164/rccm.200409-1223OC
48.McGinnis R, Shifman S, Darvasi A. Power and efficiency of the TDT and case-control design for association scans. Behav Genet.2002;32:135-44.
49.Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, Shih WL, Kao JH, Chen DS, Chen CJ. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst.2005;97:265-72.
50.Yu MW, Yang YC, Yang SY, Cheng SW, Liaw YF, Lin SM, Chen CJ. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst.2001;93:1644-51.
51.Liu K, Muse SV. PowerMarker: an integrated analysis environment for genetic marker analysis. Bioinformatics.2005;21:2128-9.
52.Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet.2003 ;73:1162-9.
53.Nielsen DM, Ehm MG, Weir BS. Detecting marker-disease association by testing for Hardy-Weinberg disequilibrium at a marker locus. Am J Hum Genet.1999;63:1531-40.
54.Benjamini Y & Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B. 1995;57:289-300.
55.Chang HC, Yu MW, Lu CF, Chiu YH, Chen CJ. Risk factors associated with hepatitis C virus infection in Taiwanese government employees. Epidemiol Infect. 2001;126:291-9.
56.Yu MW, You SL, Chang AS, Lu SN, Liaw YF, Chen CJ. Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan. Cancer Res. 1991;51:5621-5.
57.Alkhayat AH, Kraemer SA, Leipprandt JR, Macek M, Kleijer WJ, Friderici KH. Human beta-mannosidase cDNA characterization and first identification of a mutation associated with human beta-mannosidosis. Hum Mol Genet.1998 ;7:75-83.
58.Xu ZH, Otterness DM, Freimuth RR, Carlini EJ, Wood TC, Mitchell S, Moon E, Kim UJ, Xu JP, Siciliano MJ and Weinshilboum RM (2000) Human 39-phosphoadenosine 59-phosphosulfate synthetase 1 (PAPSS1) and 2 gene cloning, characterization and chromosomal localization. Biochem Biophys Res Commun 268:437–444.
59.Weinshilboum RM and Otterness DM (1994) Sulfotransferase enzymes, in Conjugation-Deconjugation Reactions in Drug Metabolism and Toxicity (Kaufmann FC ed), chapter 22, Handbook of Experimental Pharmacology series, 112, 45–78
60.Klaassen CD and Boles JW (1997) The importance of 39-phosphoadenosine-59-phosphosulfate(PAPS) in the regulation of sulfation. FASEB J 11:404–418.
61.Xu Z, Wood TC, Adjei AA, Weinshilboum RM. Human 3''-phosphoadenosine 5''-phosphosulfate synthetase: radiochemical enzymatic assay, biochemical properties, and hepatic variation. Drug Metab Dispos.2001;29:172-8.
62.Placha G, Canani LH, Warram JH, Krolewski AS. Evidence for different susceptibility genes for proteinuria and ESRD in type 2 diabetes. Adv Chronic Kidney Dis.2005;12:155-69.
63.Chiu YF, Chuang LM, Hsiao CF, Hung YJ, Lin MW, Chen YT, Grove J, Jorgenson E, Quertermous T, Risch N, Hsiung CA. An autosomal genome-wide scan for loci linked to pre-diabetic phenotypes in nondiabetic Chinese subjects from the Stanford Asia-Pacific Program of Hypertension and Insulin Resistance Family Study. Diabetes.2005;54:1200-6.
64.Aulchenko YS, Vaessen N, Heutink P, Pullen J, Snijders PJ, Hofman A, Sandkuijl LA, Houwing-Duistermaat JJ, Edwards M, Bennett S, Oostra BA, van Duijn CM. A genome-wide search for genes involved in type 2 diabetes in a recently genetically isolated population from the Netherlands. Diabetes. 2003;52:3001-4.
65.Hsueh WC, St Jean PL, Mitchell BD, Pollin TI, Knowler WC, Ehm MG, Bell CJ, Sakul H, Wagner MJ, Burns DK, Shuldiner AR. Genome-wide and fine-mapping linkage studies of type 2 diabetes and glucose traits in the Old Order Amish: evidence for a new diabetes locus on chromosome 14q11 and confirmation of a locus on chromosome 1q21-q24. Diabetes.2003;52:550-7.
66.Mori Y, Otabe S, Dina C, Yasuda K, Populaire C, Lecoeur C, Vatin V, Durand E, Hara K, Okada T, Tobe K, Boutin P, Kadowaki T, Froguel P. Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate Loci on 7p and 11p. Diabetes. 2002 ;51:1247-55.
67.Vardarli I, Baier LJ, Hanson RL, Akkoyun I, Fischer C, Rohmeiss P, Basci A, Bartram CR, Van Der Woude FJ, Janssen B. Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. Kidney Int.2002 ;62:2176-83.
68.Bowden DW, Colicigno CJ, Langefeld CD, Sale MM, Williams A, Anderson PJ, Rich SS, Freedman BI. A genome scan for diabetic nephropathy in African Americans. Kidney Int.2004;66:1517-26.
69.Daw EW, Thompson EA, Wijsman EM. Bias in multipoint linkage analysis arising from map misspecification. Genet Epidemiol.2000;19:366-80.